Aquestive Therapeutics logo
Aquestive Therapeutics
AQST | NASDAQ
Chart Builder DCF Calculator
$3.76
-$0.15 (-3.84%)
At close: Nov 16, 2026, 4:00 PM ET
$3.78
+$0.02 (+0.53%)
After-hours: Nov 16, 2026, 7:55 PM ET

Aquestive Therapeutics Company Profile

Company profile explained

Company Profile

Aquestive Therapeutics, Inc. is a pharmaceutical company focused on discovering, developing, and commercializing products to address significant unmet medical needs across both the United States and international markets. The company's commercialized portfolio includes: Sympazan, an oral soluble film formulation of clobazam for individuals with Lennox-Gastaut syndrome. Suboxone, a sublingual film containing buprenorphine and naloxone, indicated for the treatment of opioid dependence. Zuplenz, an oral soluble film of ondansetron, used to manage nausea and vomiting associated with chemotherapy and post-operative recovery. Azstarys, a once-daily medication for attention deficit hyperactivity disorder. Aquestive maintains a robust proprietary pipeline of drug candidates. These include: Libervant, a buccal soluble film formulation of diazepam currently in development for the treatment of seizures. Exservan, an oral soluble film of riluzole, aimed at treating amyotrophic lateral sclerosis (ALS). Within its complex molecule pipeline, the company is advancing: AQST-108, a sublingual film designed to deliver systemic epinephrine for conditions other than anaphylaxis. AQST-305, a sublingual film formulation of octreotide for managing acromegaly. AQST-109, an orally administered epinephrine product candidate intended for the emergency treatment of severe allergic reactions, including anaphylaxis. Furthermore, Aquestive Therapeutics played a role in the development of KYNMOBI, a sublingual film formulation of apomorphine, used to address episodic "off" periods in patients with Parkinson's disease. Established in 2004, Aquestive Therapeutics, Inc. is headquartered in Warren, New Jersey.

Key Executives

Name Position
Daniel Barber Chief Executive Officer, President & Director
Cassie Jung Chief Operating Officer
Peter E. Boyd Senior Vice President of Information Technology & Chief People Officer
Thomas A. Zalewski Chief Legal Officer & Chief Compliance Officer
A. Ernest Toth Jr. Senior VP & CFO
Lori J. Braender BSBA Corporate Secretary
Matthew Greenhawt Chief Medical Officer
Matthew William Davis Chief Development Officer
Melina T. Cioffi Senior Vice President of Regulatory Affairs
Sherry Korczynski Chief Commercial Officer

Latest SEC Filings

Date Type Title
Oct 23, 2026 4 Filing
Oct 19, 2026 8-K Current Report
Oct 16, 2026 4 Filing
Oct 16, 2026 3 Filing
Oct 15, 2026 8-K Current Report
Oct 14, 2026 8-K Current Report
Oct 07, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Oct 07, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Sep 29, 2026 8-K Current Report
Sep 25, 2026 8-K Current Report
View All SEC Filings ➞
Aquestive Therapeutics
Aquestive Therapeutics logo
Country United States
IPO Date Jul 25, 2018
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 147
CEO Daniel Barber

Contact Details

30 Technology Drive Warren, New Jersey 07059 United States

Stock Details

Ticker Symbol AQST
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001398733
CUSIP Number 03843E104
ISIN Number US03843E1047
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.